11C-acetate for Treatment Response After Radiotherapy for HCC

Feasibility of 11C-acetate in the Monitoring of Treatment Response Following Radiotherapy in Patients With Hepatocellular Carcinoma

It is thought that PET of the abdomen with 11C Acetate will provide new information regarding whether or not patient's have benefited from radiotherapy. To test this theory, the project will evaluate the potential of 11C acetate to serve as an earlier and/or better signal of treatment success.

Inclusion Criteria:

• > 18 years of age
• Subject is willing to participate in the study and has signed the study informed consent
• Subject is available and willing to comply with the protocol evaluations
• Diagnosed hepatocellular carcinoma confined to a single lobe of the liver if undergoing 90Y radioembolization
• Diagnosed hepatocellular carcinoma confined to the liver if undergoing Stereotactic Body Radiation Therapy (SBRT)
• Under consideration for 90Y radioembolization or Stereotactic Body Radiation Therapy (SBRT)

Exclusion Criteria:

• Pregnant or planning to become pregnant within the next 12 months or breast-feeding
• GFR < 45
• Life expectancy < 6 months
• Claustrophobic and cannot tolerate imaging procedures
• Weigh > 350 lb (upper weight limit of scanner beds)
• Special vulnerabilities (e.g. fetuses, neonatales, pregnant women, children, prisoners, institutionalized individuals).